Stock ISTA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News ISTA Pharmaceuticals, Inc.

Equities

US45031X2045

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for ISTA Pharmaceuticals, Inc.
2012 ISTA Pharmaceuticals, Inc. : Bausch & Lomb launches $3.48 billion credit RE

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
ISTA Pharmaceuticals, Inc. : Bausch + Lomb and ISTA Pharmaceuticals Announce Early Termination of Hart-Scott-Rodino Waiting Period
PU
ISTA Pharmaceuticals, Inc. : Bausch & Lomb launches $3.48 billion credit
RE
ISTA Pharmaceuticals, Inc. : Law Office of Brodsky & Smith, LLC Announces Investigation of ISTA Pharmaceuticals, Inc.
PR
ISTA Pharmaceuticals, Inc. : Law Offices of Howard G. Smith Announces Continued Investigation of ISTA Pharmaceuticals, Inc.
BU
ISTA Pharmaceuticals, Inc. : Law Firm Brower Piven Announces Investigation in Connection With the Acquisition of ISTA Pharmaceuticals, Inc. by Bausch + Lomb
BU
ISTA Pharmaceuticals, Inc. : Holzer Holzer & Fistel, LLC Announces Investigation into the Proposed Buyout of ISTA Pharmaceuticals, Inc.
BU
ISTA Pharmaceuticals, Inc. : ISTA Pharmaceuticals Investor Alert: The Briscoe Law Firm and Powers Taylor, LLP Investigate the Acquisition of ISTA Pharmaceuticals, Inc. by Bausch + Lomb
BU
ISTA Pharmaceuticals, Inc. : Law Offices of Howard G. Smith Announces Investigation of ISTA Pharmaceuticals, Inc.
BU
ISTA Pharmaceuticals, Inc. : Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ista Pharmaceuticals Inc.
BU
ISTA Pharmaceuticals, Inc. : Ryan & Maniskas, LLP Announces Investigation of ISTA Pharmaceuticals, Inc.
BU
ISTA Pharmaceuticals, Inc. : ISTA's Board Reiterates Commitment to Maximizing Shareholder Value Through Strategic Review Process
PU
ISTA Pharmaceuticals, Inc. : Valeant Pharmaceuticals Withdraws Offer for Acquisition of ISTA Pharmaceuticals Inc.
PR
ISTA Pharmaceuticals, Inc. : ISTA Pharmaceuticals Completes Patient Enrollment in Phase 2 Clinical Study of BEPOSONE(TM) (Bepotastine Besilate - Steroid Combination Nasal Spray) for the Treatment of Symptoms Associated With Seasonal Allergic Rhinitis
PU
ISTA Pharmaceuticals, Inc. : ISTA's Board of Directors to Review Valeant's Revised Proposal as Part of Its Ongoing Review of Strategic Options
PU
ISTA Pharmaceuticals, Inc. : ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2011 Financial Results
PU
ISTA Pharmaceuticals, Inc. : ISTA Pharmaceuticals Reports Results From the Second of Two Studies in the REMURA(TM) Phase 3 Clinical Program for Dry Eye Disease
PU
ISTA PHARMACEUTICA : ISTA Pharmaceuticals to Present at Southern California Investor Conference and Stifel Nicolaus Annual Healthcare Conference
PU
ISTA PHARMACEUTICA : ISTA Pharmaceuticals Reports Results From the First of Two Trials in the REMURA(TM) Phase 3 Clinical Program for Dry Eye Disease
PU
ISTA PHARMACEUTICA : ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2011 Financial Results
PU
ISTA PHARMACEUTICA : ISTA Pharmaceuticals Achieves 2010 Revenue and Earnings Guidance; Provides 2011 Financial Guidance and Updates Key Plans
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News ISTA Pharmaceuticals, Inc.